Combined organ failure with combination antihyperlipidemic treatment: A case of hepatic injury and acute renal failure

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 143-147

  Akoglu, Hadim ^a   Yilmaz, Rahmi ^a   Kirkpantur, Alper ^a   Arici, Mustafa ^a   Altun, Bulent ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute renal failure; Dyslipidemia; Fluvastatin; Gemfibrozil; Hepatitis; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; LACTATE DEHYDROGENASE; LIVER ENZYME; MYOGLOBIN; STATINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY DYSFUNCTION; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; MOTOR DYSFUNCTION; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MYOPATHY; NARANJO PROBABILITY SCALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RATING SCALE; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; ULTRASOUND; URINE COLOR;

ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; LIVER DISEASES; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RHABDOMYOLYSIS;

EID: 33846446412     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H251     Document Type: Article

References (32)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFTT). JAMA 1986;256:2823-8.
2. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.
5. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 suppl 1): III50-7.
6. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486-9.
7. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17. DOI 10.1345/aph.10315
8. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70.
9. Becquemont L. [Drug interactions with antilipemics] French. Therapie 2003;58:85-90.
10. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357-64.
11. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95. DOI 10.1345/aph.1A289
12. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
13. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002;3:35-40.
14. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-25.
15. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34:155-62.
16. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
17. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003;3:169-78.
18. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2.
19. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
20. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995;76(suppl 1):80A-3A.
21. Smit JW, Jansen GH, de Bruin TW, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995;76(suppl 1):126A-8A.
22. Vergoulas G, Miserlis G, Solonaki F, et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl Int 2000;13(suppl 1):S64-7.
23. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003;92:794-7.
24. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
25. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359-61.
26. Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-7.
27. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999;27:410-6.
28. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40:263-81.
29. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
30. Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995;58:412-7.
31. Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Am J Cardiol 2002;90:1388-91.
32. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996;51:433-59.